Bradley J. Monk, MD, FACS, FACOG - Chair's Take: Latest and Emerging Evidence of PARP Inhibitors in Ovarian Cancer Management - a podcast by PVI, PeerView Institute for Medical Education
from 2022-05-04T02:14:15.670530
Go online to PeerView.com/VSY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist discusses recent developments in the use of PARP inhibitors and their companion diagnostics in advanced ovarian cancer and shares insight on incorporating PARP inhibitors into individualized treatment plans to improve patient outcomes in a variety of ovarian cancer settings. Upon completion of this activity, participants should be better able to: Review the rationale of PARP inhibitors targeting DNA repair pathway mutations, as well as their validated clinical evidence in ovarian cancer, Employ PARP inhibitor therapy and their companion diagnostics, when appropriate, for patients with ovarian cancer in frontline maintenance, pretreated platinum-sensitive, pretreated platinum-refractory, and other settings, Plan strategies to prevent and/or manage the PARP inhibitor-associated adverse events, particularly in long-term use (eg, maintenance settings), in patients with ovarian cancer, Identify patients eligible for enrollment into clinical trials testing PARP inhibitors, including as combination approaches, in different treatment settings for ovarian cancer.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education